Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-25
2005-01-25
Myers, Carla J. (Department: 1637)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S359000, C514S361000, C514S362000, C514S363000, C514S364000, C514S365000, C514S372000, C514S374000, C514S378000, C514S381000, C514S383000, C514S414000, C514S418000
Reexamination Certificate
active
06846839
ABSTRACT:
The present invention relates to methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis. More specifically, this invention relates to methods for treating diseases and disorders, such as rheumatoid arthritis, endometriosis, ocular neovascularization, solid tumor growth and metastases, and excessive scarring during wound healing, with indolinone compounds.
REFERENCES:
patent: 5389661 (1995-02-01), Sircar et al.
patent: 5610173 (1997-03-01), Schwartz et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5840745 (1998-11-01), Buzzotti et al.
patent: 9622976 (1996-08-01), None
patent: WO-9640116 (1996-12-01), None
patent: 9838984 (1998-09-01), None
Abboud, “Role of platelet-derived growth factor in renal injury,”Annu. Rev. Physiol.57:297-309 (1995).
Abedi et al., “Singalling mechanisms in the regulation of vascular cell migration,”Cardiovasc. Res.30:544-556 (1995).
Abraham et al., “Human basic fibroblast growth factor: Nucleotide sequence and genomic organization,”EMBO J.5:2523-2528 (1986).
Adamis et al., “Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy,”Amer. J. Ophthalmology118:445-450 (1994).
Adamis et al., “Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate,”Arch. Ophthalmol.114:66-71 (1996).
Agapitos et al., “Immunohistochemical detection of platelet derived growth factor in the aortic wall of atherosclerotic rabbits,”Int. Angiol.15:249-251 (1996).
Aiello et al., “Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor using soluble VEGF-receptor chimeric proteins,”Proc. Natl. Acad. Sci.92:10457-10461 (1995).
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,”New England J. Med.331:1480-1487 (1994).
Alpers et al., “Identificationof platelet-derived growth factor A and B chains in human renal vascular rejection,”Am. J. Pathol.148:439-451 (1996).
Anan et al., “Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer,”Surgery119:333-339(1996).
Andrews et al. (American Veterinary Medicine Association Panel on Euthanasia), “1993 Report of the AVMA Panel on Euthanasia,”J. American Veterinary Medicine Association202(2):229-249 (1993).
Arbiser, “Angiogenesis and the skin: A primer,”Am. Acad. Derm.34:486-497 (1996).
Asano et al., “Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor,”Cancer Res.55:5296-5301 (1995).
Baffour et al., “Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: Dose response effect of basic fibroblast growth factor,”J. Vasc. Surg.16:181-191 (1992).
Barnhill et al., “Supernatants from cultured human epidermal keratinocytes stimulate angiogenesis,”Br. J. Dermatol.110:273-281 (1984).
Bates et al., “Biosynthesis of human fibroblast growth factor-5,”Mol. Cell. Biol.11:1840-1845 (1991).
Battler et al., “Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium,”J. Am. Coll. Cardio.22:2001-2006 (1995).
Ben-Av et al., “Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis,”FEBS Lett.372:83-87 (1995).
Bennet et al., “Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques,”J. Clin. Invest.95:2266-2274 (1995).
Billett et al., “Increased expression of genes for platelet-derived growth factor in circulating mononuclear cells of hypercholesterolemic patients,”Arterioscler Thromb. Vasc. Biol.16:399-406 (1996).
Brauchle et al., “Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes,”J. Biol. Chem.271:21793-21797 (1996).
Breier et al., “Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development,”Dev. Dyn.204:228-233 (1995).
Breier et al., “Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation,”Development114:521-532 (1992).
Brogi, et al., “Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only,”Circulation90:649-652 (1994).
Brookes et al., “Sequence organization of the human int-2 gene and its expression in teratocarcinoma cells,”Oncogene4:429-436 (1989).
Brown et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Adenocarcinomas of the Gastrointestinal Tract,”Cancer Research53:4727-4735 (1993).
Brown et al., “Increased expression of vascular permeability factor (VEGF) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme,”Invest. Dermatol.104:744-749 (1995).
Brown et al., “Overexpression of vascular permeability factor and its endothelial cell receptors in delayed hypersensitivity skin reactions,”J. Immunol.154:2801-2807 (1995).
Brown et al., “Uterine smooth muscle cells express functional receptors for vascular permeability factor/vascular endothelial growth factor,”Lab Invest76:245-255 (1997).
Burgess et al., “The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins,”Annu. Rev. Biochem.58:575-606 (1989).
Byrd et al., “Expression and functional expansion of fibroblast growth factor receptor T cells in rheumatoid synovium and peripheral blood of patients with rheumatoid arthritis,”Arth&Rheumat.39:914-922 (1996).
Carmeliet et al., “Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele,”Nature380:435-439 (1996).
Chabrier, “Growth factors and vascular wall,”Int. Angiol.15:100-103 (1996).
Cheng et al., “Synthesis and Michael reaction of 3,4-dimethylpyrrole,”J. Heterocyclic Chem.13:1145-1147 (1976).
Cheng, “Suppressionof glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor,”Proc. Natl. Acad. Sci. USA93:8502-8507 (1996).
Chow et al., “FGF suppresses apoptosis and induces differentiation of fibre cells in the mouse lens,”Development121:4383-4393 (1995).
Claessen-Welsh, “PDGF Receptors: Structure and mechanism of action,”Biology of Platelet-Derived Growth Factor(Westermark & Sorg, eds.), Cytokines. Basel, Karfger, 5:31-43 (1993).
Claffey et al., “Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis,”Cancer Res.56:172-181 (1996).
Colville-Nash et al., “Angiogenesis and rheumatoid arthritis: Pathogenic and therapeutic implications,”Annals. Rheumatic Diseases51:919-925 (1992).
Connolly et al., “Human vascular permeability factor,”J. Biol. Chem.264:20017-20024 (1989).
Coulier et al., “Of worms and men: An evolutionary perspective on the fibroblast growth factor and FGF receptor families,”J. Mol. Evol.44:43-56 (1997).
Cozzolino et al., “Interferon-α and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release,
Fong Annie
Hirth Klaus Peter
Shawver Laura Kay
Sun Li
Tang Peng Cho
Burrous Beth A.
Myers Carla J.
Spiegler Alexander H.
Sugen Inc.
LandOfFree
Methods for treating diseases and disorders related to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating diseases and disorders related to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating diseases and disorders related to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3437588